IF 2.8 3区医学

Eye Pub Date : 2024-08-28 DOI: 10.1038/s41433-024-03308-6

Beatriz G Armendariz, Usha Chakravarthy

引用次数: 0

Correspondence on: a model for anterior vitrectomy in real patients: simulation for practical training. 通讯：真实患者玻璃体前切除术模型：模拟实践培训。

IF 2.8 3区医学

Eye Pub Date : 2024-08-26 DOI: 10.1038/s41433-024-03296-7

Alasdair I Simpson, Jennifer Hind, David Lockington

引用次数: 0

IF 2.8 3区医学

Eye Pub Date : 2024-08-26 DOI: 10.1038/s41433-024-03284-x

Ashish Sharma, Peter K Kaiser, Ramin Tadayoni, Frank G Holz, Luke Nicholson, Clara Vazquez-Alfageme, Sobha Sivaprasad, Taku Wakabayashi, Se Joon Woo, David Sarraf, Nilesh Kumar, Nikulaa Parachuri, Carl D Regillo, Kourous A Rezaei, Arshad M Khanani, Francesco Bandello, Mahesh Shanamugam, Lalit Verma, Mangat Ram Dogra, Muralidhar Ns, Manisha Agarwal, Anat Loewenstein, Baruch D Kuppermann

引用次数: 0

Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). 更正：信息图表：治疗并延长给药时间长达 16 周的玻璃体内法尼单抗治疗新生血管性年龄相关性黄斑变性的 2 年疗效、持久性和安全性（TENAYA 和 LUCERNE 的汇总结果）。

IF 2.8 3区医学

Eye Pub Date : 2024-08-26 DOI: 10.1038/s41433-024-03309-5

Naomi Wijesingha, Aachal Kotecha, Philippe Margaron, Sobha Sivaprasad

引用次数: 0

Evolving therapeutic paradigms in ocular graft-versus-host disease. 眼部移植物抗宿主病治疗范例的演变。

IF 2.8 3区医学

Eye Pub Date : 2024-08-24 DOI: 10.1038/s41433-024-03311-x

Mouayad Masalkhi, Noura Wahoud, Bridget Moran, Ezzat Elhassadi

引用次数: 0

Vitrectomy in Small idiopathic MAcuLar hoLe (SMALL) study: conventional internal limiting membrane peeling versus inverted flap. 小特发性毛细血管瘤玻璃体切除术（SMALL）研究：传统内缘膜剥离与倒置皮瓣。

IF 2.8 3区医学

Eye Pub Date : 2024-08-24 DOI: 10.1038/s41433-024-03301-z

Matteo Fallico, Paolo Caselgrandi, Paola Marolo, Guglielmo Parisi, Enrico Borrelli, Federico Ricardi, Francesco Gelormini, Luca Ceroni, Michele Reibaldi

{"title":"Vitrectomy in Small idiopathic MAcuLar hoLe (SMALL) study: conventional internal limiting membrane peeling versus inverted flap.","authors":"Matteo Fallico, Paolo Caselgrandi, Paola Marolo, Guglielmo Parisi, Enrico Borrelli, Federico Ricardi, Francesco Gelormini, Luca Ceroni, Michele Reibaldi","doi":"10.1038/s41433-024-03301-z","DOIUrl":"https://doi.org/10.1038/s41433-024-03301-z","url":null,"abstract":"Background: To compare conventional internal limiting membrane (ILM) peeling versus inverted flap technique in small idiopathic macular hole.Methods: Retrospective, multicentre cohort study including consecutive eyes with a ≤250 μm idiopathic macular hole treated with primary vitrectomy. The primary outcome was best-corrected visual acuity (BCVA) change and macular hole closure rate. Closure patterns on optical coherence tomography (OCT) and rates of external limiting membrane (ELM) and ellipsoid zone (EZ) recovery were considered as secondary outcomes.Results: A total of 389 and 250 eyes were included in the conventional ILM peeling group and in the inverted flap group, respectively. Hole closure rate was comparable between the two groups (98.5% in the ILM peeling group and 97.6% in the inverted flap group). Mean BCVA was comparable between the two groups at baseline (p = 0.331). At 12 months, mean BCVA was 0.14 ± 0.19 logMAR in the conventional ILM peeling group and 0.17 ± 0.18 logMAR in the inverted flap group (p = 0.08). At 12 months, 73% of eyes had a U-shape closure morphology in the conventional ILM peeling group versus 55% in the inverted flap group. At 12 months, ELM recovery rate was 96% and 86% in the conventional ILM peeling group and in the inverted flap group, respectively (p < 0.001); EZ recovery rate was 78% and 69%, respectively (p = 0.04).Conclusions: The inverted flap technique provides no advantages in terms of visual outcome and closure rate in small idiopathic macular hole surgery. Additionally, this technique seems to impair postoperative restoration of external retinal layers compared with conventional peeling.","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Risks and regulation of rubber scattershot in Switzerland: a narrative review. 更正：瑞士橡胶散射的风险和监管：叙述性综述。

IF 2.8 3区医学

Eye Pub Date : 2024-08-23 DOI: 10.1038/s41433-024-03291-y

Anna Fierz

引用次数: 0

A model for anterior vitrectomy in real patients: is it safe, ethical and necessary? 在真实患者身上进行玻璃体前切除术的模型：是否安全、合乎道德且必要？

IF 2.8 3区医学

Eye Pub Date : 2024-08-21 DOI: 10.1038/s41433-024-03306-8

Georgios D Panos, Alexander Foss, Craig Wilde, Mary Awad, Harminder Dua

引用次数: 0

Infographic: clinical trial of standalone microinvasive Glaucoma surgery implants for open Angel Glaucoma: Hydrus versus iStent. 信息图：独立微创青光眼手术植入物治疗开放性天使型青光眼的临床试验：Hydrus 与 iStent。

IF 2.8 3区医学

Eye Pub Date : 2024-08-21 DOI: 10.1038/s41433-024-03280-1

Mei Ken Low, Alexa Korb, Jason Yap, Muhammad Zarnab Munawar, Amirah Amin Ariff, Christin Henein, Rashmi G Mathew

引用次数: 0

Use of immunomodulators in non-infectious uveitis: lights and shadows. 在非感染性葡萄膜炎中使用免疫调节剂：光明与阴影。

IF 2.8 3区医学

Eye Pub Date : 2024-08-19 DOI: 10.1038/s41433-024-03294-9

Carolina Bernal-Morales, Athimalaipet V Ramanan, Carlos Pavesio

{"title":"Use of immunomodulators in non-infectious uveitis: lights and shadows.","authors":"Carolina Bernal-Morales, Athimalaipet V Ramanan, Carlos Pavesio","doi":"10.1038/s41433-024-03294-9","DOIUrl":"https://doi.org/10.1038/s41433-024-03294-9","url":null,"abstract":"Non-infectious uveitis (NIU) is one of the leading causes of sight impairment worldwide. Corticosteroids are the mainstay treatment for acute NIU, although their known systemic and ocular side effects limit their long-term use. The most common types of immunosuppressants used as steroid-sparing treatment are non-biologic drugs, particularly antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine) and biologic drugs, mainly TNF-α inhibitors such as Adalimumab or Infliximab. Antimetabolites have shown their effectiveness in the treatment of NIU in individual and comparative studies, being methotrexate and mycophenolate mofetil usually preferred over azathioprine. The choice of which antimetabolite to use at first is not well defined, and decisions usually depend on the patient's characteristics and the physician's preferences. Treatment of NIU with biologic drugs, and particularly TNF-α inhibitors, has significantly increased in the last years and is considered an important alternative in patients not responding to first-line immunomodulators such as antimetabolites. However, data regarding how different immunomodulators or biologic drugs perform in different NIU is still limited, and little is known about the optimization of both biologic and non-biologic drugs when used in NIU. Further randomized clinical trials and comparative studies are required to achieve more understanding and better results when addressing complicated NIU. The purpose of this review is to provide a comprehensive overview of the use of non-biologic and biologic drugs in NIU, which may be useful for clinicians in their daily practice, and to address those aspects that are less known about these treatments as well as their weaknesses.","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eye最新文献